These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36256646)

  • 1. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
    Vanni T; Thomé BC; Sparrow E; Friede M; Fox CB; Beckmann AM; Huynh C; Mondini G; Silveira DH; Viscondi JYK; Braga PE; Silva AD; Salomão MDG; Piorelli RO; Santos JP; Gattás VL; Lucchesi MBB; Oliveira MMM; Koike ME; Kallas EG; Campos LMA; Coelho EB; Siqueira MAM; Garcia CC; Miranda MD; Paiva TM; Timenetsky MDCST; Adami EA; Akamatsu MA; Ho PL; Precioso AR
    PLoS One; 2022; 17(10):e0274943. PubMed ID: 36256646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
    Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
    Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
    Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
    JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.
    Akamatsu MA; Sakihara VA; Carvalho BP; de Paiva Abrantes A; Takano MAS; Adami EA; Yonehara FS; Dos Santos Carneiro P; Rico S; Schanoski A; Meros M; Simpson A; Phan T; Fox CB; Ho PL
    PLoS One; 2020; 15(6):e0233632. PubMed ID: 32492039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
    Madan A; Ferguson M; Rheault P; Seiden D; Toma A; Friel D; Soni J; Li P; Innis BL; Schuind A
    Vaccine; 2017 Apr; 35(15):1865-1872. PubMed ID: 28302407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Ortiz JR; Spearman PW; Goepfert PA; Cross K; Buddy Creech C; Chen WH; Parker S; Overton ET; Dickey M; Logan HL; Wegel A; Neuzil KM
    Vaccine; 2022 May; 40(23):3253-3262. PubMed ID: 35465983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Winokur P; El Sahly HM; Mulligan MJ; Frey SE; Rupp R; Anderson EJ; Edwards KM; Bernstein DI; Schmader K; Jackson LA; Chen WH; Hill H; Bellamy A;
    Vaccine; 2021 Feb; 39(8):1339-1348. PubMed ID: 33485646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
    Madan A; Collins H; Sheldon E; Frenette L; Chu L; Friel D; Drame M; Vaughn DW; Innis BL; Schuind A
    Vaccine; 2017 Aug; 35(35 Pt B):4621-4628. PubMed ID: 28720281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
    Diallo A; Victor JC; Feser J; Ortiz JR; Kanesa-Thasan N; Ndiaye M; Diarra B; Cheikh S; Diene D; Ndiaye T; Ndiaye A; Lafond KE; Widdowson MA; Neuzil KM
    Vaccine; 2018 Oct; 36(43):6424-6432. PubMed ID: 30224199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects.
    Chanthavanich P; Versage E; Van Twuijver E; Hohenboken M
    Vaccine; 2021 Nov; 39(47):6930-6935. PubMed ID: 34711436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Oil-in-Water adjuvant significantly increased influenza A/H7N9 split virus Vaccine-Induced circulating follicular helper T (cT
    Lai L; Rouphael N; Xu Y; Kabbani S; Beck A; Sherman A; Anderson EJ; Bellamy A; Weiss J; Cross K; Mulligan MJ
    Vaccine; 2022 Nov; 40(49):7065-7072. PubMed ID: 36273986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
    Feldman RA; Fuhr R; Smolenov I; Mick Ribeiro A; Panther L; Watson M; Senn JJ; Smith M; Almarsson Ӧ; Pujar HS; Laska ME; Thompson J; Zaks T; Ciaramella G
    Vaccine; 2019 May; 37(25):3326-3334. PubMed ID: 31079849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
    Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
    Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.